Oncology Advances January 2017

New Bcl-2 Inhibitor Studies Expand Options for Patients with Hematologic Malignancies, Build on Decades of Research Hematologic oncologists in the Center

Anthony Letai, MD, PhD, and Matthew S. Davids, MD, MMSc

Hematologic oncologists in the Center for Hematologic Oncology at Dana-Farber/Brigham and Women’s Cancer Center are leading studies of venetoclax (ABT-199), a first-in-class Bcl-2 inhibitor approved for patients with relapsed chronic lymphocytic leukemia with 17p deletion.

> Read the full article

h rule

Team Investigates Key Factors in Patient Decision-making Amid Growing Rates and Lack of Survival Benefit in Contralateral Prophylactic Mastectomy

Survival Benefit Contralateral Prophylactic Mastectomy  

While rates of contralateral prophylactic mastectomy (CPM) more than tripled between 2002 and 2012, researchers at Dana- Farber/ Brigham and Women’s Cancer Center (DF/BWCC) have found no survival benefit among patients choosing CPM over breast conservation. DF/BWCC researchers are conducting ongoing research to examine the primary factors that contribute to patients’ decisions to undergo CPM.

> Read the full article

h rule

Liquid Biopsy for Lung Cancer Delivers Faster Diagnosis and Targeted Treatments

Dr Geoffrey Oxnard and Dr Cloud Paweletz  

Developed by experts at Dana-Farber/Brigham and Women’s Cancer Center, a new blood test using rapid plasma genotyping to detect epidermal growth factor receptor (EGFR) and KRAS mutations is enabling much more rapid diagnosis and commencement of targeted therapies for patients with non-small cell lung cancer.

> Read the full article

h rule

Enhanced Recovery After Surgery Protocol Demonstrates Reduction in Complications and Length of Stay

Ronald Bleday MD and Mark Preston MD MPH  

Surgical teams at Dana-Farber/Brigham and Women’s Cancer Center are expanding their use of the Enhanced Recovery After Surgery (ERAS®) protocol based on the results seen among hundreds of patients.

> Read the full article

h rule

More Articals

Share this newsletter

Clinical Trials

> Review available trials
> Research advances

Next Day Access for New Patients in Boston

Dana-Farber/Brigham and Women's Cancer Center in Boston now offers next business day appointments for new patients for whom quick access is important. An oncology nurse will contact those patents within a few hours to facilitate the process. To refer a patient, or schedule a consultation with a member of our team, please call 1-877-332-4294.

Updates on Precision Cancer Medicine

Dana-Farber/Brigham and Women’s Cancer Center has a new online resource to provide comprehensive information on precision cancer medicine. Learn more.

Upcoming CME Programs
ASH 2016 Highlights
Saturday, January 21, 2017
Boston Marriott Newton Hotel Newton, MA

> Learn more and register
Topics in Gastrointestinal Cancer
Saturday, February 4, 2017
Four Seasons Hotel
Boston, MA

> Learn more and register

Tune in to Our New Podcast Series
How We Treat Colon and
Rectal Cancer

Harvard Medical School© 2017 Dana-Farber/Brigham and Women's Cancer Center, Boston, MA
Phone: (877) DFCI-BWH / (877) 332-4294
www.dfbwcc.org